之江生物：公司将围绕从诊断向“诊断+治疗”延伸的全产业链布局

Core Viewpoint - The company is focusing on enhancing its research and innovation efforts while also prioritizing external growth opportunities through mergers, acquisitions, and strategic partnerships to expand its business scope and develop a second growth curve [1] Group 1: Research and Innovation - The company is continuously increasing its investment in research and innovation [1] - There is a strategic shift from diagnostics to a full industry chain layout that includes both "diagnostics + treatment" [1] Group 2: Business Expansion - The company aims to steadily expand its business areas through mergers, equity participation, and strategic collaborations [1] - The focus is on cultivating a second growth curve to promote high-quality and sustainable development [1] Group 3: Financial Management - The company is exercising caution in its financial management to enhance long-term value [1] - There is a commitment to returning value to investors who have placed their trust in the company [1]